JP2005506971A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005506971A5 JP2005506971A5 JP2003518542A JP2003518542A JP2005506971A5 JP 2005506971 A5 JP2005506971 A5 JP 2005506971A5 JP 2003518542 A JP2003518542 A JP 2003518542A JP 2003518542 A JP2003518542 A JP 2003518542A JP 2005506971 A5 JP2005506971 A5 JP 2005506971A5
- Authority
- JP
- Japan
- Prior art keywords
- accession number
- mrp1
- mrp1 gene
- gene
- position corresponding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01117608 | 2001-07-23 | ||
| EP02011710 | 2002-05-24 | ||
| PCT/EP2002/008200 WO2003013533A2 (en) | 2001-07-23 | 2002-07-23 | Methods for improved treatment of cancer with irinotecan based on mrp1 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005506971A JP2005506971A (ja) | 2005-03-10 |
| JP2005506971A5 true JP2005506971A5 (https=) | 2006-01-05 |
Family
ID=26076655
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003518546A Withdrawn JP2005501840A (ja) | 2001-07-23 | 2002-07-23 | 癌の改良された治療のための手段および方法 |
| JP2003518543A Withdrawn JP2005504759A (ja) | 2001-07-23 | 2002-07-23 | Ｃｙｐ３ａ５に基づいたがんの改善治療の手段及び方法 |
| JP2003518542A Withdrawn JP2005506971A (ja) | 2001-07-23 | 2002-07-23 | Ｍｒｐ１に基づいたがんの改善治療の手段及び方法 |
| JP2003518545A Withdrawn JP2005505526A (ja) | 2001-07-23 | 2002-07-23 | Ｕｇｔ１ａ１に基づいたがんの改善治療の手段及び方法 |
| JP2003518544A Withdrawn JP2005508312A (ja) | 2001-07-23 | 2002-07-23 | Ｍｄｒ１に基づいた癌治療の改善のための手段および方法 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003518546A Withdrawn JP2005501840A (ja) | 2001-07-23 | 2002-07-23 | 癌の改良された治療のための手段および方法 |
| JP2003518543A Withdrawn JP2005504759A (ja) | 2001-07-23 | 2002-07-23 | Ｃｙｐ３ａ５に基づいたがんの改善治療の手段及び方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003518545A Withdrawn JP2005505526A (ja) | 2001-07-23 | 2002-07-23 | Ｕｇｔ１ａ１に基づいたがんの改善治療の手段及び方法 |
| JP2003518544A Withdrawn JP2005508312A (ja) | 2001-07-23 | 2002-07-23 | Ｍｄｒ１に基づいた癌治療の改善のための手段および方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20050032724A1 (https=) |
| EP (5) | EP1408973A2 (https=) |
| JP (5) | JP2005501840A (https=) |
| AU (5) | AU2002328945A1 (https=) |
| CA (5) | CA2454627A1 (https=) |
| WO (5) | WO2003013537A2 (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4096037B2 (ja) * | 2002-08-12 | 2008-06-04 | 国立大学法人滋賀医科大学 | グルクロン酸転移酵素遺伝子の変異解析による薬剤代謝活性の予測方法 |
| US6916627B2 (en) | 2002-11-27 | 2005-07-12 | St. Jude Children's Research Hospital | ATM kinase compositions and methods |
| US7108992B2 (en) | 2002-11-27 | 2006-09-19 | St. Jude Children's Research Hospital | ATM kinase compositions and methods |
| ES2308208T3 (es) | 2003-05-30 | 2008-12-01 | University Of Chicago | Metodos y composiciones para predecir la toxicidad del irinotecano. |
| WO2005028645A1 (ja) * | 2003-09-24 | 2005-03-31 | Kyushu Tlo Company, Limited | ＭＤＲ１遺伝子の５’制御領域におけるＳＮＰｓ |
| BRPI0415079A (pt) * | 2003-10-06 | 2006-12-12 | Novartis Ag | biomarcadores para prognóstico de diarréia induzida por droga |
| JP2005245362A (ja) * | 2004-03-05 | 2005-09-15 | Kyowa Medex Co Ltd | 肺癌および頭頸部癌の発症危険率を予測する方法 |
| US20070207149A1 (en) * | 2004-04-27 | 2007-09-06 | Wellstat Biologics Corporation | Cancer treatment using viruses and camptothecins |
| ES2429041T3 (es) * | 2004-06-18 | 2013-11-12 | Genentech, Inc. | Combinación de un agente quimioterapéutico y un antagonista de un producto génico para tratar tumores |
| WO2006076288A2 (en) * | 2005-01-11 | 2006-07-20 | Five Prime Therapeutics, Inc. | Dna constructs for long-term expression of intravascularly injected naked dna |
| JP2007060967A (ja) * | 2005-08-30 | 2007-03-15 | Tokyo Institute Of Technology | 遺伝子多型の検出方法および薬物のスクリーニング方法 |
| US20090325156A1 (en) * | 2005-11-10 | 2009-12-31 | Government of the United States of America, as Represented by Secretary, Dept. of Human Services | Materials and methods for abcb1 polymorphic variant screening, diagnosis, and treatment |
| KR101107911B1 (ko) * | 2006-11-30 | 2012-01-25 | 아크레이 가부시키가이샤 | Ｕｇｔ1ａ1 유전자 증폭용 프라이머 셋트, 그것을 포함하는ｕｇｔ1ａ1 유전자 증폭용 시약 및 그 용도 |
| WO2010099508A1 (en) * | 2009-02-26 | 2010-09-02 | Theraquest Biosciences, Inc. | Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use |
| WO2011031974A1 (en) * | 2009-09-10 | 2011-03-17 | Southern Research Institute | Acridine analogs in the treatment of gliomas |
| EP2542155B1 (en) | 2010-03-01 | 2015-11-04 | TAU Therapeutics LLC | Method for imaging a disease |
| JP2011250726A (ja) * | 2010-06-01 | 2011-12-15 | Toyo Kohan Co Ltd | イリノテカンの副作用の発生危険度を判定する方法及びそのためのキット |
| JP5945270B2 (ja) | 2010-07-20 | 2016-07-05 | バヴァリアン・ノルディック・アクティーゼルスカブ | 発現産物を採取するための方法 |
| US9717724B2 (en) | 2012-06-13 | 2017-08-01 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies |
| AU2013202947B2 (en) | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
| KR102271848B1 (ko) * | 2013-11-01 | 2021-07-01 | 피트니 파마슈티컬스 피티와이 리미티드 | 암 치료용 약학적 배합물 |
| CA2962476C (en) * | 2014-09-26 | 2023-09-26 | Hi-Stem Ggmbh | Novel methods for sub-typing and treating cancer |
| JP2016088919A (ja) * | 2014-11-11 | 2016-05-23 | 国立研究開発法人産業技術総合研究所 | イベルメクチン又はミルベマイシンｄを有効成分として含む抗癌剤 |
| CN107208163B (zh) * | 2015-02-17 | 2021-01-08 | 国立大学法人山口大学 | 辅助对伊立替康副作用的发生风险的预测的方法 |
| US11318131B2 (en) | 2015-05-18 | 2022-05-03 | Ipsen Biopharm Ltd. | Nanoliposomal irinotecan for use in treating small cell lung cancer |
| JP7042739B2 (ja) | 2015-08-20 | 2022-03-28 | イプセン バイオファーム リミティド | 癌処置のためのリポソーム型イリノテカン及びｐａｒｐ阻害薬を使用する併用療法 |
| TW202400181A (zh) | 2015-08-21 | 2024-01-01 | 英商益普生生物製藥有限公司 | 使用包含微脂伊立替康(irinotecan)及奧沙利鉑(oxaliplatin)之組合療法治療轉移性胰臟癌的方法 |
| CN110402163A (zh) | 2016-11-02 | 2019-11-01 | 易普森生物制药有限公司 | 使用包括脂质体伊立替康、奥沙利铂、5-氟尿嘧啶(和甲酰四氢叶酸)的组合疗法治疗胃癌 |
| CN109939115B (zh) * | 2019-05-06 | 2021-11-02 | 河南中医药大学 | 一种治疗放射性直肠炎的复方栓剂 |
| US20230310478A1 (en) * | 2020-09-02 | 2023-10-05 | Ann And Robert H. Lurie Children's Hospital Of Chicago | Methods and compositions for the treatment of pulmonary hypertension and cancer |
| CN114224875B (zh) * | 2021-11-04 | 2023-08-11 | 中南大学湘雅医院 | 醇类化合物的新用途及抗肿瘤药物 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998037892A1 (en) * | 1997-02-27 | 1998-09-03 | Pharmacia & Upjohn Company | Tamoxifen as a therapy to reduce irinotecan hydrochloride-induced diarrhea |
| AU2592600A (en) * | 1998-12-23 | 2000-07-31 | G.D. Searle & Co. | Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
| US6395481B1 (en) * | 1999-02-16 | 2002-05-28 | Arch Development Corp. | Methods for detection of promoter polymorphism in a UGT gene promoter |
| CA2295429A1 (en) * | 2000-01-06 | 2001-07-06 | Michael Michael | Treatment or prevention of diarrhea |
| DE60120917T2 (de) * | 2000-01-26 | 2007-01-25 | Schering Corp. | Kombinationspräparat zur krebstherapie |
| EP1286671B1 (en) * | 2000-05-15 | 2006-04-05 | Celgene Corporation | Compositions for the treatment of colorectal cancer comprising thalidomide and irinotecan |
| WO2002028380A2 (en) * | 2000-10-06 | 2002-04-11 | Bristol-Myers Squibb Company | Oral dosage forms for administration of the combination of tegafur, uracil, folinic acid, and irinotecan and method of using the same |
-
2002
- 2002-07-23 AU AU2002328945A patent/AU2002328945A1/en not_active Abandoned
- 2002-07-23 CA CA002454627A patent/CA2454627A1/en not_active Abandoned
- 2002-07-23 WO PCT/EP2002/008218 patent/WO2003013537A2/en not_active Ceased
- 2002-07-23 CA CA002454640A patent/CA2454640A1/en not_active Abandoned
- 2002-07-23 WO PCT/EP2002/008200 patent/WO2003013533A2/en not_active Ceased
- 2002-07-23 AU AU2002328952A patent/AU2002328952A1/en not_active Abandoned
- 2002-07-23 JP JP2003518546A patent/JP2005501840A/ja not_active Withdrawn
- 2002-07-23 WO PCT/EP2002/008220 patent/WO2003013535A2/en not_active Ceased
- 2002-07-23 CA CA002454637A patent/CA2454637A1/en not_active Abandoned
- 2002-07-23 AU AU2002328953A patent/AU2002328953A1/en not_active Abandoned
- 2002-07-23 AU AU2002328950A patent/AU2002328950A1/en not_active Abandoned
- 2002-07-23 JP JP2003518543A patent/JP2005504759A/ja not_active Withdrawn
- 2002-07-23 EP EP02764757A patent/EP1408973A2/en not_active Withdrawn
- 2002-07-23 EP EP02764762A patent/EP1408974A2/en not_active Withdrawn
- 2002-07-23 US US10/484,577 patent/US20050032724A1/en not_active Abandoned
- 2002-07-23 AU AU2002331290A patent/AU2002331290A1/en not_active Abandoned
- 2002-07-23 WO PCT/EP2002/008219 patent/WO2003013534A2/en not_active Ceased
- 2002-07-23 JP JP2003518542A patent/JP2005506971A/ja not_active Withdrawn
- 2002-07-23 CA CA002454643A patent/CA2454643A1/en not_active Abandoned
- 2002-07-23 EP EP02767255A patent/EP1408975A2/en not_active Withdrawn
- 2002-07-23 WO PCT/EP2002/008217 patent/WO2003013536A2/en not_active Ceased
- 2002-07-23 EP EP02764764A patent/EP1408972A2/en not_active Ceased
- 2002-07-23 CA CA002454648A patent/CA2454648A1/en not_active Abandoned
- 2002-07-23 EP EP02764763A patent/EP1438050A2/en not_active Withdrawn
- 2002-07-23 JP JP2003518545A patent/JP2005505526A/ja not_active Withdrawn
- 2002-07-23 JP JP2003518544A patent/JP2005508312A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005506971A5 (https=) | ||
| JP2005505526A5 (https=) | ||
| JP2005504759A5 (https=) | ||
| JP2005501840A5 (https=) | ||
| Huttner et al. | The mouse genome encodes a single homolog of the antimicrobial peptide human β‐defensin 1 | |
| Ho et al. | Increased risk of developing hepatocellular carcinoma associated with carriage of the TNF2 allele of the− 308 tumor necrosis factor-α promoter gene | |
| JP2020152729A5 (https=) | ||
| JP2006507794A5 (https=) | ||
| Cucurull et al. | Targeting KRAS in lung cancer beyond KRAS G12C inhibitors: the immune regulatory role of KRAS and novel therapeutic strategies | |
| US11136625B2 (en) | Gene expression signatures predictive of subject response to a multi-kinase inhibitor and methods of using the same | |
| Coon et al. | Prognostic implications of loss of heterozygosity at 8p21 and 9p21 in head and neck squamous cell carcinoma | |
| Hsiao et al. | Hypoxia inducible factor‐1α gene polymorphism G1790A and its interaction with tobacco and alcohol consumptions increase susceptibility to hepatocellular carcinoma | |
| JP2006518186A5 (https=) | ||
| KR102238912B1 (ko) | Dna 메틸화 변이 및 종양 변이 부담을 이용한 면역항암치료 반응성 예측방법 | |
| Campomenosi et al. | p53 is frequently mutated in Barrett's metaplasia of the intestinal type. | |
| JP2012521758A (ja) | プロテアソーム阻害剤による治療に対する末梢性ニューロパシー応答を評価するためのバイオマーカー | |
| Park et al. | MDM2 309T> G polymorphism and risk of lung cancer in a Korean population | |
| JP2009515524A5 (https=) | ||
| Shahbazi et al. | Novel functional polymorphism in IGF-1 gene associated with multiple sclerosis: a new insight to MS | |
| Lemos-Gonzalez et al. | Absence of activating mutations in the EGFR kinase domain in Spanish head and neck cancer patients | |
| JP2005512558A5 (https=) | ||
| Song et al. | Transduction effect of antisense K-ras on malignant phenotypes in gastric cancer cells | |
| Borrego et al. | Germline control of somatic Kras mutations in mouse lung tumors | |
| ES2254382T3 (es) | Polimorfismos del gen transportador de 5-hidroxitriptamina. | |
| JP2004154120A5 (https=) |